Business Wire

MA-NETWITNESS

7.6.2022 18:02:05 CEST | Business Wire | Press release

Share
NetWitness Launches Comprehensive XDR Offerings for Next Generation Security

NetWitness , a globally trusted provider of cybersecurity technologies and incident response, today announced NetWitness XDR, a family of products and capabilities delivering comprehensive detection and response on premise, in the cloud or as a hybrid of the two. This new offering and product architecture delivers the full range of deployment options enterprises seek today to meet their unique cybersecurity needs and use cases.

NetWitness XDR delivers a robust set of capabilities enabling extended detection and response (XDR) and helping customers stay ahead of the most sophisticated cyber threats. These include:

  1. Unified collection, data, and visibility across multiple security layers
  2. Automatic enrichment of data using any technical or business source
  3. A wide toolset of detection technologies including, but not limited to, advanced behavioral analysis
  4. External and internal threat intelligence to identify known security risks and threat actors
  5. Truly insightful context, visualization, and investigation tools
  6. Threat hunting tools and methodologies to identify previously unknown threats
  7. Highly repeatable and measurable incident investigation and response processes
  8. A strong array of both automated and human response options

“NetWitness has enjoyed the trust of some of the world’s most security sensitive organizations because of its unique ability to monitor the entire attack surface across the network, endpoint, cloud, IoT, logs and more,” said CEO of RSA and NetWitness, Rohit Ghai. “We have been delivering XDR capability to the market for several years and today we are delighted to announce new innovations in the platform and reintroduce it to the market as NetWitness XDR.”

Under this new model, NetWitness XDR will be comprised of three main product lines that showcase its uniquely powerful support for all XDR use cases. NetWitness Platform XDR 12 is the newest major release of NetWitness Platform. This technology stack, typically deployed as customer-managed software or hosted by MSSPs, has been enhanced to focus on detection capabilities that identify threats faster and decrease their impact. The company’s new cloud-native SaaS version will be known as NetWitness Vision XDR and is currently in design preview. The third product line, NetWitness XDR Cloud Services, is a set of optional SaaS applications that take advantage of the cloud’s inherent elastic nature to deliver flexible and cost-effective components which can be used to augment either Platform XDR or Vision XDR.

“Our network-forward approach allows us to stand out in this emerging space and highlights NetWitness XDR’s ability to detect across customers’ growing number of systems and devices,” said Director of Product Management and Research, Kevin Bowers. “We are embracing the belief that the best XDR must be consumable on prem, in the cloud, and hybrid.”

Developed initially in 1996, NetWitness began as a government-sponsored research project to inspect network packets for cyberthreats and tools to detect and respond to them. Since then, the technology has continuously evolved and been innovated to tackle today’s most complex attacks. NetWitness now features fully integrated components for network, log, endpoint and IoT detection and response that drive its threat intelligence and security orchestration platform, NetWitness Orchestrator. With its long history and global footprint, NetWitness XDR integrates directly with the world’s most critical and widely deployed tools, as well as many specialized and industry-specific solutions.

NetWitness XDR will host demonstrations at its booth at RSA Conference this year for Platform XDR and Vision XDR.

To learn more, visit www.netwitness.com .

ABOUT NetWitness

NetWitness, an RSA® Group Business, provides comprehensive and highly scalable threat detection and response capabilities for organizations around the world. The NetWitness Platform delivers complete visibility combined with applied threat intelligence and user behavior analytics to detect, prioritize, investigate threats, and automate response. This empowers security analysts to be more efficient and stay ahead of business-impacting threats. For more information, visit netwitness.com.

©2022 RSA Security LLC or its affiliates. All rights reserved. RSA and the RSA logo are trademarks of RSA Security LLC or its affiliates. For a list of RSA trademarks visit https://www.rsa.com/en-us/company/rsa-trademarks . Other trademarks are trademarks of their respective owners. RSA believes the information in this document is accurate. The information is subject to change without notice.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Backed by Investments Exceeding $1 Billion, PCI Pharma Services Announces Major Expansion of US Sterile Fill-Finish and Drug-Device Delivery Combination Capabilities27.4.2026 16:00:00 CEST | Press release

As pharma manufacturers prioritize US supply chain resilience, highlights include high-speed isolator filling lines for prefilled syringes, cartridges and vials, and drug-device combination assembly and packaging. PCI Pharma Services (“PCI”) – a world-leading integrated global contract development and manufacturing organization (CDMO) focused on innovative biologic and small molecule therapies – announced a series of major infrastructure investments that substantially deepen its sterile fill-finish and advanced drug delivery capabilities. As pharma manufacturers and their development partners increasingly prioritize US supply chain resilience, PCI’s latest investments come as part of a broader commitment exceeding $1 billion across the CDMO’s US and European operations, reinforcing its ability to provide seamless support for drug product development and manufacturing, clinical trial supply and drug-device combination assembly from clinical stages through commercial launch – all underpi

Pure Lithium Appoints Renowned Battery Expert Dr. Yuan Gao to Board of Directors27.4.2026 15:53:00 CEST | Press release

Pure Lithium Corporation, a vertically integrated lithium metal battery technology company, is pleased to announce that world-renowned inventor and battery expert Dr. Yuan Gao has joined the company’s Board of Directors. Dr. Gao has been an invaluable member of Pure Lithium’s Scientific Advisory Board since October of 2023. "We are thrilled to have Dr. Gao join our board as we focus on rapidly scaling our technology in the most capital efficient manner possible,” said Pure Lithium Founder, Chairman and CEO Emilie Bodoin. “Dr. Gao is a brilliant scientist who also has deep commercial expertise, a rare combination. He is also unique in the industry because his experience spans the entire battery materials value chain, including all of Pure Lithium’s verticals. His insights over the years have been critical in advancing our technology, and his experience as a director of public companies will strengthen our board.” Dr. Gao commented: “I am thrilled to join the board of Pure Lithium Corpor

Taiho Oncology, Taiho Pharmaceutical and Araris Biotech AG Advance ADC ARC-02 into Phase 1 Clinical Development27.4.2026 15:00:00 CEST | Press release

Phase 1 dose-escalation trial represents the first clinical trial of a product developed using the AraLinQ™ ADC technology and marks Taiho’s expansion into the clinical development of ADCs for oncology Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Araris Biotech AG (“Araris”) today announced that the U.S. Food and Drug Administration (FDA) has completed its Investigational New Drug (IND) review period for ARC-02, an antibody-drug conjugate (ADC) being developed for the treatment of non-Hodgkin lymphoma, enabling Taiho Oncology to initiate a Phase 1 dose-escalation clinical trial of ARC-02. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427127507/en/ Taiho Pharmaceutical acquired Araris Biotech in March 2025, expanding Taiho group’s capabilities in biologics and ADC research and development. Araris is a spin-off of the Paul Scherrer Institute and ETH in Switzerland focused on the development of antibody-drug co

Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 202627.4.2026 15:00:00 CEST | Press release

Premier global event to highlight how organizations are bringing data to life to power everything from AI to BI Boomi, the data activation company, today announced Boomi World 2026, its premier annual user conference, taking place May 11 - 14, 2026 in Chicago, IL. The event will bring together customers, partners, and industry leaders from around the world to explore how data activation is transforming the enterprise and accelerating the path to AI-driven outcomes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427600340/en/ Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 2026 Boomi World 2026 will spotlight data activation — bringing data to life to power AI, analytics, and intelligent automation. Attendees will gain firsthand insights into how the Boomi Enterprise Platform enables businesses to unify data, streamline operations, and innovate faster in an increasingly agentic world.

Axinn Appoints Rachael Philbin as Chief Innovation Officer27.4.2026 15:00:00 CEST | Press release

Appointment Reflects Firm's Vision for the Future of Legal Practice Axinn, Veltrop & Harkrider LLP today announced the appointment of Rachael Philbin as Chief Innovation Officer, reinforcing the firm’s continued investment in advanced solutions and technology for legal services delivery. Philbin joins from Proskauer Rose LLP, where she served as Innovation & Transformation Officer. Based in Axinn's New York office, she will lead the firm’s AI and legal technology initiatives as well as knowledge management efforts, accelerating adoption and integration across its antitrust, intellectual property, and litigation practices. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427277725/en/ Rachael Philbin joins Axinn, Veltrop & Harkrider LLP as Chief Innovation Officer. “As Axinn continues to grow, we are making deliberate investments in the capabilities that enable our lawyers to deliver service and results at the highest level

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye